The successful outcome of this study represents an important milestone in Dr. Reddy's commitment to make highquality biosimilar products more accessible and affordable
Sun Pharma will have exclusive rights to commercialise Nidlegy for indications of skin cancers in the territories of Europe, Australia and New Zealand. Philogen will complete pivotal clinical trials for the product in Europe
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)
Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
The target boundary includes biogenic land?related emissions and removals from bioenergy feedstock
Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.
The approval paves the way for consolidating the company’s position in Kenya and other African markets as part of its global expansion plans
Leading Research-driven Pharma Company Combats Antibiotic Resistance and Demonstrates Innovation in Medical Solutions
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
Subscribe To Our Newsletter & Stay Updated
